# ARAY — Accuray Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ARAY  
**Sources:** 22  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-aray-accuray-inc-catalysts-narrative-risks-6183

---

## Overview (point-in-time: as of Oct 2–4, 2026)

Accuray (NASDAQ: ARAY) is a radiation-therapy company whose products center on the CyberKnife and TomoTherapy platforms (including the Radixact system), founded in 1990 with roughly 809 employees [[1]](https://intellectia.ai/news/stock/accuray-q3-fiscal-2026-earnings-call-insights), [[16]](https://stockanalysis.com/stocks/aray/). As of the Oct 2, 2026 close, the stock traded near $0.28 (+5.16% that day), with a market capitalization of about $33.6M, ~119.4M shares outstanding, and a 52-week range of $0.22–$2.10 [[16]](https://stockanalysis.com/stocks/aray/), [[17]](https://finance.yahoo.com/quote/ARAY/). The stock has been in a steep downtrend: approximately -65.7% year-to-date and roughly -83% over the past year relative to the S&P 500 [[14]](https://finance.yahoo.com/quote/ARAY/news/), [[17]](https://finance.yahoo.com/quote/ARAY/).

## Recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-aray-accuray-inc-catalysts-narrative-risks-6183 (free to sign up)._
